CA2303482A1 - Activateurs transcriptionnels chimeres, compositions et applications afferentes - Google Patents
Activateurs transcriptionnels chimeres, compositions et applications afferentes Download PDFInfo
- Publication number
- CA2303482A1 CA2303482A1 CA002303482A CA2303482A CA2303482A1 CA 2303482 A1 CA2303482 A1 CA 2303482A1 CA 002303482 A CA002303482 A CA 002303482A CA 2303482 A CA2303482 A CA 2303482A CA 2303482 A1 CA2303482 A1 CA 2303482A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- nucleic acid
- domain
- transcription
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Landscapes
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Cette invention a trait à des activateurs transcriptionnels chimères dont la protéine contient au moins un domaine d'activation de transcription composite ("TAD") et au moins un domaine de liaison de l'ADN ("DBD"). Le TAD composite comporte une région polypeptidique continue comportant deux, sinon davantage, régions polypeptidiques constituantes (également dénommées "indicateurs d'activation") dont deux au moins se présentent ensemble dans le même produit génique d'origine naturelle. Dans certaines réalisations, la protéine chimère comporte un domaine de liaison aux ligands pour une activation allostérique, par exemple, un domaine récepteur capable de lier un ligand perméant de cellule comme la tétracycline ou un analogue de celle-ci ou un stéroïde tel que RU486 ou l'ecdysone. Dans ces cas, l'activateur de transcription chimère active de manière sélective la transcription d'un gène cible en présence du ligand respectif. Dans d'autres réalisations, l'activateur de transcription chimère est capable d'activer de manière constitutive une expression du gène cible, c'est à dire, sans que la présence d'un ligand ne soit nécessaire.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/015219 WO1999010508A1 (fr) | 1997-08-27 | 1997-08-27 | Activateurs transcriptionnels chimeres, compositions et applications afferentes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2303482A1 true CA2303482A1 (fr) | 1999-03-04 |
Family
ID=22261527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002303482A Abandoned CA2303482A1 (fr) | 1997-08-27 | 1997-08-27 | Activateurs transcriptionnels chimeres, compositions et applications afferentes |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1003886A1 (fr) |
JP (1) | JP2001514007A (fr) |
AU (1) | AU752129B2 (fr) |
CA (1) | CA2303482A1 (fr) |
IL (1) | IL134643A0 (fr) |
WO (1) | WO1999010508A1 (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2375490A1 (fr) * | 1999-06-18 | 2000-12-28 | Ariad Gene Therapeutics, Inc. | Facteurs de transcription oca-b chimeriques |
CA2398010A1 (fr) | 2000-01-24 | 2001-07-26 | The Trustees Of Columbia University In The City Of New York | Crible in vivo mettant en application des inducteurs chimiques de dimerisation |
WO2001062780A1 (fr) * | 2000-02-24 | 2001-08-30 | The Salk Institute For Biological Studies | Systeme d'expression genique a base de recepteurs chimeres |
AU2000256183A1 (en) * | 2000-06-16 | 2002-01-02 | Ariad Gene Therapeutics, Inc. | Chimeric hsf transcription factors |
MXPA03007492A (es) * | 2001-02-20 | 2004-10-15 | Rheogene Holdings Inc | Receptores de retinoide x quimerico y su uso en un sistema de expresion de gen inducible basado en receptor de ecdisona novedoso. |
EP1435779A4 (fr) | 2001-09-24 | 2005-06-01 | Sangamo Biosciences Inc | Modulation de cellules souches au moyen de proteines a doigts de zinc (zfp) |
US7083918B2 (en) | 2002-04-24 | 2006-08-01 | The Trustees Of Columbia University In The City Of New York | Bacterial small-molecule three-hybrid system |
AU2004274957B2 (en) | 2003-09-19 | 2009-02-05 | Sangamo Therapeutics, Inc. | Engineered zinc finger proteins for regulation of gene expression |
WO2006033859A2 (fr) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Production de proteines: compositions et methodes |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
CA2793633A1 (fr) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Systeme d'ablation de transgene induit pharmacologiquement |
EP2699688A1 (fr) | 2011-04-20 | 2014-02-26 | The Trustees Of The University Of Pennsylvania | Régimes et compositions pour l'immunisation passive médiée par aav contre des agents pathogènes en suspension dans l'air |
WO2016200543A2 (fr) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation |
SG11201808426XA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
SG11201907611WA (en) | 2017-02-28 | 2019-09-27 | Univ Pennsylvania | Influenza vaccines based on aav vectors |
HRP20240257T1 (hr) | 2017-02-28 | 2024-05-24 | The Trustees Of The University Of Pennsylvania | Adeno-povezani virusni (aav) clade f vektor i njegova uporaba |
SG11202003479TA (en) | 2017-10-18 | 2020-05-28 | Regenxbio Inc | Fully-human post-translationally modified antibody therapeutics |
CA3079565A1 (fr) | 2017-10-18 | 2019-04-25 | Regenxbio Inc. | Traitement de maladies oculaires et d'un cancer du colon metastatique avec un piege a vegf avec modification post-traductionnelle humain |
CN113966236A (zh) | 2019-04-03 | 2022-01-21 | 再生生物股份有限公司 | 眼睛病状的基因疗法 |
TW202106708A (zh) | 2019-04-24 | 2021-02-16 | 美商銳進科斯生物股份有限公司 | 全人類轉譯後修飾之抗體治療劑 |
JP2022545967A (ja) | 2019-08-26 | 2022-11-01 | リジェネックスバイオ インコーポレイテッド | 完全ヒト翻訳後修飾抗VEGF Fabを用いる糖尿病性網膜症の処置 |
KR20220081365A (ko) | 2019-10-07 | 2022-06-15 | 리젠엑스바이오 인크. | 아데노-연관 바이러스 벡터 약제학적 조성물 및 방법 |
EP4214242A1 (fr) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Anticorps vectorisés pour thérapie antivirale |
EP4213890A1 (fr) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Lanadelumab vectorisé et administration de celui-ci |
CA3197342A1 (fr) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Therapie genique pour manifestations oculaires de maladie cln2 |
CN116528892A (zh) | 2020-10-28 | 2023-08-01 | 再生生物股份有限公司 | 用于眼部适应症的载体化抗TNF-α抗体 |
WO2022094157A1 (fr) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Anticorps vectorisés anti-cgrp et anti-récepteur de cgrp et leur administration |
WO2022094255A2 (fr) | 2020-10-29 | 2022-05-05 | Regenxbio Inc. | Anticorps de facteur xii vectorisés et leur administration |
AU2021369833A1 (en) | 2020-10-29 | 2023-06-08 | Regenxbio Inc. | Vectorized tnf-alpha antagonists for ocular indications |
TW202237850A (zh) | 2020-12-01 | 2022-10-01 | 賓州大學委員會 | 具有組織特異性靶向基序的新穎構成物及含有其之組成物 |
CN112661820B (zh) * | 2020-12-31 | 2021-12-14 | 中国科学院天津工业生物技术研究所 | 天山根瘤菌转录调控蛋白MsiR突变蛋白及其在刀豆氨酸生物传感器中的应用 |
AR125406A1 (es) | 2021-04-23 | 2023-07-12 | Univ Pennsylvania | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen |
TW202325845A (zh) | 2021-10-02 | 2023-07-01 | 賓州大學委員會 | 新穎aav衣殼及含其之組成物 |
WO2023147304A1 (fr) | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Capsides d'aav pour une transduction cardiaque améliorée et un ciblage du foie |
WO2023201308A1 (fr) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Thérapie génique pour le traitement d'une maladie oculaire |
WO2023205610A2 (fr) | 2022-04-18 | 2023-10-26 | Regenxbio Inc. | Capsides aav hybrides |
WO2023215806A2 (fr) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | Anticorps anti-complément vectorisés et agents de complément et leur administration |
WO2023215807A1 (fr) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | INHIBITEURS VECTORISÉS ANTI-TNF-α POUR INDICATIONS OCULAIRES |
WO2024022474A1 (fr) * | 2022-07-29 | 2024-02-01 | 南京百斯杰生物工程有限公司 | Activateur transcriptionnel chimérique et son utilisation |
WO2024073669A1 (fr) | 2022-09-30 | 2024-04-04 | Regenxbio Inc. | Traitement de maladies oculaires avec des vecteurs viraux recombinés codant un fab anti-vegf |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0882128A1 (fr) * | 1996-02-23 | 1998-12-09 | Ariad Pharmaceuticals, Inc. | Essai a base de cellules |
WO1997044447A2 (fr) * | 1996-05-03 | 1997-11-27 | President And Fellows Of Harvard College | Systeme d'activation de transcription, activateurs et leurs utilisations |
-
1997
- 1997-08-27 IL IL13464397A patent/IL134643A0/xx unknown
- 1997-08-27 WO PCT/US1997/015219 patent/WO1999010508A1/fr not_active Application Discontinuation
- 1997-08-27 CA CA002303482A patent/CA2303482A1/fr not_active Abandoned
- 1997-08-27 EP EP97940681A patent/EP1003886A1/fr not_active Withdrawn
- 1997-08-27 JP JP2000507816A patent/JP2001514007A/ja not_active Withdrawn
- 1997-08-27 AU AU42402/97A patent/AU752129B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
EP1003886A1 (fr) | 2000-05-31 |
AU4240297A (en) | 1999-03-16 |
JP2001514007A (ja) | 2001-09-11 |
AU752129B2 (en) | 2002-09-05 |
IL134643A0 (en) | 2001-04-30 |
WO1999010508A1 (fr) | 1999-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU752129B2 (en) | Chimeric transcriptional activators and compositions and uses related thereto | |
US6015709A (en) | Transcriptional activators, and compositions and uses related thereto | |
US6117680A (en) | Compositions and methods for regulation of transcription | |
JP3817739B2 (ja) | キメラdna結合性タンパク質 | |
US6479653B1 (en) | Compositions and method for regulation of transcription | |
US6326166B1 (en) | Chimeric DNA-binding proteins | |
US5919667A (en) | Modular assembly retroviral vectors and uses thereof | |
US6306649B1 (en) | Heterologous transcription factors | |
WO1996006110A1 (fr) | Proteines composites se fixant a de l'adn et substances et procedes concernant ces proteines | |
WO1997011176A2 (fr) | Proteines associees a cycline kinases dependantes de la cycline ckd, et utilisations qui y sont liees | |
CA2346962A1 (fr) | Regulation fondee sur fk506 d'evenements biologiques | |
WO2000078951A1 (fr) | Facteurs de transcription oca-b chimeriques | |
WO2001098507A1 (fr) | Facteurs de transcription hsf chimeres | |
WO2001018036A2 (fr) | Methodes et reactifs permettant de reguler l'expression genique | |
Liu | Characterization of negative regulatory proteins involved in tissue specific MMTV expression | |
MXPA99003470A (en) | Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use | |
Jo | Epigenetic regulation of gene structure and function with a cell-permeable DNA site-specific recombinase | |
MXPA97006928A (es) | Sistema de expresion condicional |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |